HIV Prevention Research

We need volunteers to help investigate a twice-yearly injection form of PrEP to see if it could reduce the chances of getting HIV through sex. Join our study!

Eligibility Requirements & Location

Having receptive anal sex with 1 or more partners

No HIV test in the past 3 months

16+ years old

Conducted in Chapel Hill, NC

Study Background

Even though a variety of prevention options exist, HIV remains a serious health concern for many people around the world.

In the United States, socioeconomic inequity, racism, stigma, homophobia, transphobia, and other factors have led to higher rates of HIV in some communities. PURPOSE2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine lencapavir, helps reduce the chance of getting HIV through sex.

The study was designed to include groups who are underrepresented in HIV prevention trials and are disproportionately affected by the HIV epidemic.

PURPOSE2 is being conducted in the United States, South Africa, Peru, and Brazil, and will include cisgender men, transgender women, transgender men, and gender non-binary individuals who have sex with partners assigned male at birth.

Find out more about PURPOSE2 to see if you could be a part of advancing HIV prevention and changing medical research for the better.

Additional Information

Our goal is to determine whether a twice-yearly injection of an investigational PrEP medicine, lenacapavir, helps reduce the chance of getting HIV through sex.

You may qualify to participate in this study if you meet the following criteria.

Key Criteria:

  • 16+ years old
  • Identify as a transgender woman, transgender man, gender non-binary individual, or cisgender man
  • Having receptive anal sex with partners assigned male at birth
  • Sexually active with 1+ partners
  • Have not tested for HIV in the past 3 months
  • Have not used oral PrEP (F/TDF or F/TAF) in the past 12 weeks
  • Have never used long-acting systemic PrEP (cabotegravir or islatravir)
  • Not pregnant, nursing, or likely to become pregnant

The first part of the study is a single visit that involves blood work and an HIV test. The purpose of this is to assess the overall HIV incidence in our community.

The second part of the study is an option for HIV-negative individuals who are willing to participate in receiving investigational PrEP. They will receive a daily pill and an injection given every 6 months. There will only be one active drug and one placebo. The active drug received will either be investigational lenacapavir or F/TDF.

Afterward, you may have the option to enroll in an extension phase where everyone receives investigational lenacapavir.

There is no cost for you to participate in our research program. Participants will receive the following:
  • No-cost health exams and lab work
  • Counseling and care referrals
  • Compensation for study-related time and travel